University of California

Shantha West, Inc.

Viventia Biotech Inc.

Nascent Biotech, Inc.

Sci-clone, Inc.

Glassy, Mark C.

Gupta, Rishab K.

Mark C Glassy

Yoshihide Hagiwara

Harold H Handley

Hideaki Hagiwara

Sonjoy Mukerjee

Subhra Chakrabarti

Keiji Koda

Helena R Chang

Rishab K Gupta

Ideaki Hagiwara

Charles Surh

Compositions and methods related to antibodies or antibody fragments which are capable of crossing the blood brain barrier are provided.

Enhanced delivery of drugs to the brain

The invention relates to antibodies that bind to antigens, such as antigens associated with hyperproliferating cells, and methods of treating hyperproliferative disorders. The invention antibodies are useful for treating hyperproliferative disorders, such as neoplasia.

Antibodies that recognize hyperproliferative cells and methods of making and using same

Carcinoma associated antigen (SK1) and monoclonal antibodies and methods for detecting and ameliorating malignant disease. The monoclonal antibodies are specifically reactive with epitopes present on SK1.

Carcinoma associated antigen (SK1) monoclonal antibodies against SK1, methods of producing these antibodies and uses therefor

CLNH5-specific hybridomas, human monoclonal antibodies and their uses are provided. The antibodies distinguish a human neoplastic cell from a normal cell of the same tissue type. The monoclonal antibodies find use in therapy and diagnosis, both in vitro and in vivo.

Human-Human CLNH5-specific antibodies

CLNH11-specific hybridomas, human monoclonal antibodies and their uses are provided. The antibodies distinguish a human neoplastic cell from a normal cell of the same tissue type. The monoclonal antibodies find use in therapy and diagnosis, both in vitro and in vivo.

CLNH11-specific antibodies

CLNH5 and CLNH11 specific hybridomas, human monoclonal antibodies and their uses are provided. The antibodies distinguish a human neoplastic cell from a normal cell of the same tissue type. The monoclonal antibodies find use in therapy and diagnosis, both in vitro and in vivo.

Human-human hybridom for neoplasms CLNH5 and CLNH11 specific antibody

CLNH5 and CLNH11-specific hybridomas, human monoclonal antibodies and their uses are provided. The antibodies distinguish a human neoplastic cell from a normal cell of the same tissue type. The monoclonal antibodies find use in therapy and diagnosis, both in vitro and in vivo.

Methods of determining the presence of a neoplasm with CLNH5- and

Carcinoma associated antigen (SK1) monoclonal antibodies against SK1,

Novel hybridomas, human monoclonal antibodies and their uses are provided. The antibodies distinguish a human neoplastic cell from a normal cell of the same tissue type. The monoclonal antibodies find use in therapy and diagnosis, both in vitro and in vivo.

Human-human hybridomas for neoplasms

Human-human hybrid cell lines that synthesize and secrete monoclonal antibodies against antigenic determinants on cancer cells, generated by fusing a human lymphoblastoid B cell line to human lymphocytes, and therapeutic and diagnostic uses of the monoclonal antibodies in both cancer treatment and research is disclosed.

Human-human hybrid cell lines that produce antibodies against antigenic

Novel hybridomas, human monoclonal antibodies, and their uses are provided. Specifically CLNH5 is a human-human hybridoma which secretes IgM monoclonal antibodies specific for cervical of carcinomas. The monoclonal antibodies can find use in therapy and diagnosis, both in vitro and in vivo. The hybridoma CLNH5 was deposited at the A.T.C.C. for patent purposes as defined in M.P.E.P. 608.01(p) on Jan. 28, 1983 and given A.T.C.C. Accession No. HB8206.

Growing community of inventors

San Diego, CA, United States of America

Mark C Glassy